Literature DB >> 4134716

Assessment of response to treatment in advanced breast cancer. British Breast Group.

.   

Abstract

Entities:  

Mesh：

Year:  1974        PMID： 4134716

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study.

Authors:  Sangang Wu; Qun Li; Yuliang Zhu; Jiayuan Sun; Fengyan Li; Huanxin Lin; Xunxing Guan; Zhenyu He
Journal:  Cancer Biother Radiopharm       Date:  2013-06-27       Impact factor: 3.099

2.  Cellular effects of tamoxifen in primary breast cancer.

Authors:  J F Robertson; I O Ellis; R I Nicholson; A Robins; J Bell; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

3.  Biological factors of prognostic significance in locally advanced breast cancer.

Authors:  J F Robertson; I O Ellis; D Pearson; C W Elston; R I Nicholson; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.

Authors:  J F Robertson; A R Dixon; R I Nicholson; I O Ellis; C W Elston; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Prospective assessment of the role of five tumour markers in breast cancer.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; J Pearson; R W Blamey; A Howell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Authors:  R I Nicholson; R A McClelland; J M Gee; D L Manning; P Cannon; J F Robertson; I O Ellis; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

7.  Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11.

Authors:  M R Price; A J Clarke; J F Robertson; C O'Sullivan; R W Baldwin; R W Blamey
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer.

Authors:  Amit Agrawal; John F R Robertson; K L Cheung
Journal:  World J Surg Oncol       Date:  2011-09-09       Impact factor: 2.754

9.  "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer.

Authors:  Amit Agrawal; John F R Robertson; K L Cheung
Journal:  World J Surg Oncol       Date:  2006-07-05       Impact factor: 2.754

10.  Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents.

Authors:  Amit Agrawal; John F R Robertson; K L Cheung
Journal:  World J Surg Oncol       Date:  2006-07-11       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.